Table 1 Epidemiologic and Program Data for Zambia
From: Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study
Variable | Value | Source |
|---|---|---|
Population (2005) | 11,478,000 | [56] |
Live births/1,000 population (2007) | 40.78 | [57] |
Live births per year | 468,073 | |
Percent of global BCG vaccine coverage | 0.398% | [34] |
Percent of target population vaccinated with BCG | 92% | [34] |
Gross National Income per capita (US$) 2005 | $500 | [58] |
Life expectancy at birth (years) | 38.4 | [58] |
All cause mortality | Age specific | [59] |
New estimated TB smear-positive incidence per 100,000 (2005) | 247 | [1] |
Annual risk of TB infection (ARI) | 4.94% | |
Probability of being diagnosed and treated for LTBI | 1% | [20]* |
Completion of LTBI treatment | 67% | [21] |
HIV prevalence (2006) | 9.4% | [10] |
HIV incidence per annum | 0.96% | Calculated from [22] |
DOTS coverage (2005) | 100% | [1] |
DOTS case detection rate (2005) | 52% | [1] |
Initial drug resistance | Â | Â |
   Single drug resistance | 8.5% | [60] |
   Multi drug resistance†| 1.8% | [61] |
DOTS new case treatment outcomes (2005) | Â | [1] |
   Cure/complete | 83% |  |
   Default/transfer/not evaluated | 8% |  |
   Die | 8% |  |
   Fail | 1% |  |
DOTS re-treatment outcomes (2005) | Â | [1] |
   Cure/complete | 78% |  |
   Default/transfer/not evaluated | 7% |  |
   Die | 13% |  |
   Fail | 2% |  |